Edwards Lifesciences Corporation (NYSE: EW) provided financial guidance for 2026 and reaffirmed its 2025 outlook during its annual investor conference, according to a company statement.
The medical device company projects 2026 constant currency sales growth of 8% to 10%, with total sales expected to reach $6.4 billion to $6.8 billion. The company forecasts adjusted earnings per share of $2.80 to $2.95 for 2026, representing approximately 11% growth at the midpoint.
Edwards reaffirmed its previously increased 2025 total company constant currency sales growth guidance at the high end of 9% to 10%, with earnings per share of $2.56 to $2.62.
For 2026, the company expects its transcatheter aortic valve replacement (TAVR) segment to generate sales of $4.6 billion to $4.9 billion, representing 6% to 8% constant currency growth. The transcatheter mitral and tricuspid therapies (TMTT) division is projected to achieve sales of $740 million to $780 million, with growth of 35% to 45%. Surgical segment sales are expected to reach $1.05 billion to $1.13 billion with mid-single digit growth.
The company anticipates adjusted operating margin expansion of approximately 100 basis points at the midpoint for 2026, with margins projected at 28% to 29%. Adjusted gross profit margin is expected to be 78% to 79%.
"As we enter 2026, we are poised for sustainable growth and long-term value creation," said Bernard Zovighian, Edwards' chief executive officer. "For the more than 20 million structural heart patients worldwide, we are continuing to bring novel and differentiated innovations and world-class evidence to transform care."
Edwards outlined longer-term targets, including reaching approximately 10% average annual constant currency sales growth with earnings per share leverage. The company expects its TMTT business to reach $2 billion by 2030.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.